Comment on 'Sustained discontinuation of infliximab with a raising-dose strategy after obtaining remission in patients with rheumatoid arthritis: the RRRR study, a randomised controlled trial' by Tanaka et al

Ann Rheum Dis. 2021 Nov;80(11):e172. doi: 10.1136/annrheumdis-2019-216557. Epub 2019 Nov 19.
No abstract available

Keywords: TNF-alpha; anti-TNF; disease activity; rheumatoid arthritis; treatment.

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't
  • Comment

MeSH terms

  • Antirheumatic Agents* / therapeutic use
  • Arthritis, Rheumatoid* / drug therapy
  • Humans
  • Infliximab / therapeutic use


  • Antirheumatic Agents
  • Infliximab